Semaglutide Poison Control Calls Top 8,000 by 2023 as Dosing Errors Surge After 2021 Approval
Updated
Updated · ScienceDaily · Jul 15
Semaglutide Poison Control Calls Top 8,000 by 2023 as Dosing Errors Surge After 2021 Approval
2 articles · Updated · ScienceDaily · Jul 15
Summary
U.S. poison centers logged more than 8,000 GLP-1-related calls in 2023, up from roughly 1,000 to 1,500 a year before mid-2021, with semaglutide dominating the increase.
The UT San Antonio-led analysis tied the jump to semaglutide’s 2021 FDA approval for chronic weight management, which expanded use far beyond diabetes patients.
Many cases involved preventable therapeutic mistakes rather than intentional misuse, especially taking Ozempic or Wegovy daily instead of weekly and starting at the highest dose instead of tapering up.
Researchers said better patient education from prescribers and pharmacists could curb many incidents, while noting semaglutide’s broader public-health impact and still-evolving long-term safety profile.
With Ozempic overdoses soaring, are unregulated compounded drugs fueling a hidden public health crisis?
Could AI predict the next Ozempic-style crisis before thousands are harmed by dosing errors?
The Alarming Rise in Semaglutide Poison Control Calls Post-2021: Dosing Errors, Compounded Risks, and Regulatory Gaps
Overview
Since June 2021, there has been a sharp rise in semaglutide-related poison control calls, drawing growing concern from the medical community. Research published in 2026 highlights that many of these incidents are due to preventable dosing errors, such as patients confusing daily and weekly doses. The problem is made worse by compounded semaglutide products, which often lack proper standardization and oversight, and by the challenges of telehealth prescriptions that can lead to poor patient education. This situation underscores the urgent need for better guidance, stricter regulation, and clear communication to protect patient safety and address this emerging public health issue.